NephroDi Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NephroDI Therapeutics is a rare disease biotech targeting nephrogenic diabetes insipidus (NDI), a severe pediatric orphan condition causing extreme thirst and urine output. Its core asset is a novel, selective AMPK activator designed to concentrate urine without causing hypoglycemia, a key limitation of existing AMPK drugs. The company has secured a significant development partnership with Otsuka Pharmaceutical and The McQuade Center for Strategic R&D (MSRD), providing non-dilutive funding and expertise to advance its lead candidate. Led by a seasoned CEO with a strong translational track record and founded by leading renal researchers, NephroDI is positioned to address a high unmet need with no approved therapies.

NephrologyRare DiseasesPediatrics

Technology Platform

Novel class of small molecule AMPK activators designed to selectively promote renal water reabsorption without causing systemic hypoglycemia.

Opportunities

First-in-class therapy for a severe pediatric orphan disease with no approved pharmacological treatment, representing a 100% market capture opportunity.

The strategic partnership with Otsuka/MSRD provides non-dilutive funding, de-risks development, and offers a potential path to global commercialization.

Orphan drug designations can provide extended market exclusivity, expedited regulatory pathways, and potential for a Priority Review Voucher.

Risk Factors

High scientific risk that a novel, selective AMPK mechanism will prove safe and effective in human trials for NDI.

The company is a single-asset, preclinical-stage entity, making it highly vulnerable to clinical or regulatory failure.

Commercial challenges include diagnosing a rare disease, reaching a small global patient population, and achieving reimbursement for a likely high-cost therapy.

Competitive Landscape

There are no approved pharmacological therapies specifically for congenital NDI, making NephroDI's program a potential first-in-class. Competitive approaches are limited to symptomatic management (thiazide diuretics, NSAIDs) which are off-label, often ineffective, and carry significant side effects. Other research-stage approaches may target different pathways (e.g., chaperones for mutant V2 receptors), but NephroDI's AMPK activator appears to be the most advanced in a novel mechanistic class.

More companies in Small Molecule Drugs →More companies in United States →